Monday, October 12, 2026

Moderna Stock Is 4% So Far Today

ViaNews Editorial Team

December 11, 2020

Moderna Stock Is 4%  So Far Today
Shares of Moderna 4.5% to $162.69 at 11:10 EST on Friday, after two sessions in a row of . The Nasdaq Stock Market is 0.23% to $12,376.90, following yesterday's upward trend, This seems, , a somewhat trend today. Moderna's last close was $155.69, 9.72% its 52-week high of $178.50.

Moderna's Sales

Moderna's sales growth is 1428.1% for the quarter and 13065.3% for the next. The company's growth estimates for the quarter is a negative 48.6% and positive 565.7% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Top and Bottom Yearly Value

Moderna's stock is at $162.69 at 11:10 EST, its 52-week high of $178.50 and way its 52-week low of $17.68.

Moderna's Moving Average

Moderna's is way its 50-day moving average of $101.27 and way its 200-day moving average of $76.37.

Previous days news about Moderna

Moderna says Swiss government has increased its Covid vaccine order to 7.5 million doses from 4.5 million. According to MarketWatch on Tue Dec 8, "Moderna Inc. said Tuesday the Swiss government has increased its order for Moderna's COVID-19 vaccine candidate to 7.5 million doses from an original 4.5 million." Moderna offers U.S. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, "Moderna Inc. could offer a fail-safe option that will allow the U.S. to get enough Covid-19 shots to inoculate most Americans if the government can'€™t reach an agreement to quickly buy more vaccine from Pfizer Inc., which plans to honor its contracts with other countries."
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,371 source documents archived
Query this data → isubstrate.com